Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CDH17 CAR-T cells
- Development stage
- Unknown
- Lead developer
- Guangzhou Bio-gene Technology
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
Anti-CDH17 CAR-T cells is an autologous chimeric antigen receptor (CAR) T-cell therapy targeting Cadherin-17 (CDH17), a calcium-dependent cell adhesion protein frequently overexpressed in gastrointestinal cancers and other solid tumors. Developed by the 920th Hospital of Joint Logistics Support Force of the People's Liberation Army of China in collaboration with Guangzhou Bio-gene Technology, the therapy involves the genetic modification of a patient's own T cells to express a CAR specific for CDH17. Upon infusion following lymphodepleting chemotherapy with fludarabine and cyclophosphamide, these modified T cells are designed to recognize and eliminate CDH17-expressing tumor cells. It is currently being evaluated in Phase I clinical trials for patients with advanced CDH17-positive solid tumors who have exhausted standard treatment options.
- Other names
- CDH17 CAR-TCDH-17 CAR-TCDH 17 CAR-Tanti-CDH17 chimeric antigen receptor T-cellsanti-CDH-17 chimeric antigen receptor T-cellsanti-CDH 17 chimeric antigen receptor T-cells
02
Targets
CDH17 (Cadherin-17)
Beyond the preview
Go deeper on anti-CDH17 CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CDH17 CAR-T cells.